Drug Profile
Research programme: haematological disorders therapeutics - Phenomix
Alternative Names: PHX 1117Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Phenomix Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haematological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-disorders in USA
- 16 Jul 2004 Preclinical trials in Haematological disorders in USA (unspecified route)